Biomarkers of reversed remodeling after electrical or pharmacological cardioversion of atrial fibrillation - REVERSE AF

Academisch Medisch Centrum0 个研究点目标入组 160 人开始时间: 待定最近更新: 2024年4月23日

适应症

试验速览

暂无简介。

•- Paroxysmal, persistent or longstanding persistent AF
•- Undergoing electrical or pharmacological cardioversion
•- Adequate oral anticoagulation according to guidelines with oral anticoagulants or NOACs
•- Atrial thrombosis ruled out by TEE according to guidelines
•- Age > 18 years.
•- Legally competent and willing and able to sign informed consent

•we refer to protocol p. 12-13 for a complete list of exlusion criteria
•- INR < 2 and not on NOAC treatment in patients with an indication for OAC
•- Signs of cardiogenic shock: systolic BP< 90mmHg, urine output <0.5ml/kg/h, respiratory rate >22
•- Unable or unwilling to comply with study procedures
•- Permanent AF accepted by the patient and physician
•- Presence of severe mitral regurgitation or stenosis or history of valvular surgery
•- AF with a generally reversible cause (cardiac surgery, pulmonary embolism, hyperthyroidism)
•- Chronic inflammatory disease or evidence of active infection (as evidenced by increased white blood cell count, elevated CRP level or fever > 38,5 °C)
•- NYHA class IV heart failure symptoms or left ventricular ejection fraction < 25%
•- Multivessel coronary artery disease or recent (<3months) ischemic cardiac disease

发起方